Many PTAB appeal briefs are not answered by the Examining Corps, thereby leading to favorable results for the patent applicants

The patent specification did not support a claim to a specific dose of 480 mg/day of DMF, sold under the brand name Tecfidera for the treatment of MS

Held: Written description cases are intensively fact-oriented and a disclosure with isolated examples does not support claimed ranges with lower and upper bounds